At a glance
- Originator Neurogen Corporation
- Developer Aventis Pharmaceuticals; Neurogen Corporation
- Class Antidepressants; Anxiolytics
- Mechanism of Action Corticotropin releasing hormone inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Major depressive disorder
Most Recent Events
- 07 Jan 2002 Discontinued-Preclinical for Depression in USA (Unknown route)
- 21 Dec 2001 Neurogen and Aventis are collaborating in the development of the CRF antagonist programme
- 11 Jan 2001 The CRF antagonist programme is available for licensing (http://www.neurogen.com)